DKK1 and cancer: As discussed in more detail in Section 5 and Section 6, targeting osteocyte-derived factors regulating bone resorption (i.e., RANKL) or formation (i.e., sclerostin or DKK-1) also has an impact on the progression of cancers that grow in bone.